The appearance of multi-drug resistant strains of malaria poses a major challenge to human health and validated drug targets are urgently required. To define a protein's function in vivo and thereby validate it as a drug target, highly specific tools are required that modify protein function with minimal cross-reactivity. While modern genetic approaches often offer the desired level of target specificity, applying these techniques is frequently challenging-particularly in the most dangerous malaria parasite, Plasmodium falciparum. Our hypothesis is that such challenges can be addressed by incorporating mutant proteins within oligomeric protein complexes of the target organism in vivo. In this manuscript, we provide data to support our hypothesis by demonstrating that recombinant expression of mutant proteins within P. falciparum leverages the native protein oligomeric state to influence protein function in vivo, thereby providing a rapid validation of potential drug targets. Our data show that interference with aspartate metabolism in vivo leads to a significant hindrance in parasite survival and strongly suggest that enzymes integral to aspartate metabolism are promising targets for the discovery of novel antimalarials.
| INTRODUC TI ON
The parasite Plasmodium falciparum is responsible for the most lethal form of human malaria (World Health Organization, 2017) . The spreading of P. falciparum in the human host depends on the availability of specific metabolites during its blood stage (Kirk & Saliba, 2007; Lindner, Meissner, Schettert, & Wrenger, 2013) . The metabolism of these external nutrients represents a key-step for parasite proliferation, and it is believed to be essential for its survivability.
Although these metabolic steps would open new avenues for drug discovering targeting P. falciparum, the validation of these metabolic steps remains challenging due to limitations of applicability of probe techniques in P. falciparum and dependence upon reverse genetics (Meissner et al., 2016) . This highlights the necessity of development of novel validation techniques capable of simplifying the validation of potential targets in P. falciparum-as well as other parasitic organisms. The examination of interaction surfaces between subunits of oligomeric proteins might offer a relatively straightforward alternative to this process (Meissner et al., 2016) .
Protein oligomerization, the assembly of two or more copies of a single protein into one object, is a feature shared by all organisms and is present in more than 60% of all protein structures currently available within the Protein Data Bank (PDB; Hashimoto, Nishi, Bryant, & Panchenko, 2011) . The biological importance, physicochemical properties, and evolutionary aspects of protein oligomerization have been recently summarized (Hashimoto & Panchenko, 2010; Hashimoto et al., 2011; Nishi, Hashimoto, Madej, & Panchenko, 2013) . Furthermore, lower degree of evolutionary conservation of the oligomeric interfaces (Caffrey, Somaroo, Hughes, Mintseris, & Huang, 2004; Valdar & Thornton, 2001 ), as well as high specificity and binding affinity between the cognate partners, could successfully be utilized in drug target validation (Lunev et al., 2018) . Based on these features, we hypothesized that the introduction of functionally incompetent forms of an enzyme into the native oligomeric assembly could be exploited in the analysis of biochemical pathways in vivo, particularly in cases where standard techniques (e.g., RNAi/knock in/out) have a low success rate.
The aspartate metabolism pathway within P. falciparum contains a number of oligomeric enzymes making it an ideal system to test our hypothesis that oligomeric self-assembly can be used to modulate in vivo behavior. Aspartate interconversion is essential for nitrogen metabolism of all organisms. In Plasmodium species, it was also proposed to play a key role in de novo pyrimidine biosynthesis as well as energy metabolism (Wrenger et al., 2011) . Plasmodial aspartate aminotransferase (PfAspAT) and malate dehydrogenase (PfMDH) catalyzes the reversible reaction from aspartate + 2-oxoglutarate to oxaloacetate + glutamate and malate + NAD to oxaloacetate + NADH, respectively. The crystal structure of PfAspAT has been previously solved (Wrenger et al., 2011) . As reported,
PfAspAT is a homo-dimer with a molecular weight of 48.42 kDa per monomer (Wrenger et al., 2011) . Similarly to the previously described AspAT of E. coli (Jäger, Moser, Sauder, & Jansonius, 1994) , each subunit consists of three major domains: an N-terminal arm (residues 1-14), a large coenzyme-binding domain (residues 36-321) and a smaller domain (residues 15-36 and 322-404) . The Nterminal arm domain (residues 1-14) distal from either active site is thought to stabilize the PfAspAT dimer and is necessary for activity, as truncated species lacking the N-terminal extension showed significantly reduced activity while retaining dimeric structure (Wrenger et al., 2011) . The two active sites of PfAspAT are formed in a cleft between the big and small domains near the oligomeric interface and each active site pocket is composed of residues contributed from both subunits. Previous experiments where PfAspAT was selectively inhibited in vitro using a polypeptide chain consisting of first 50 PfAspAT amino acids (Wrenger et al., 2011) confirm the hypothesis that oligomeric interfaces show significantly higher sequence divergence amongst homologs and thus offer potential in specific interference with a target protein.
The structure PfMDH has also been recently solved, and we have provided an insight into the role of oligomeric assembly in the regulation of PfMDH activity (Lunev et al., 2018) . PfMDH possesses a tetrameric conformation where each monomer is comprised of 326 residues and is composed of two major domains: an N-terminal cofactor-binding domain containing a parallel structure of six betasheets (Rossmann-fold) and C-terminal substrate-binding domain.
Our previous results suggested that a correctly formed tetrameric assembly of PfMDH is essential for activity (Lunev et al., 2018) .
Indeed, the introduction of a tryptophan residue at one of the interfaces facilitating oligomerization (V190W) results in disruption of the tetramer, breaking it down into two dimers, and a significant reduction in activity. Co-purification and western blot experiments with mixed lysates of recombinantly expressed wild-type PfMDH (Streptagged) and PfMDH-V190W (His 6 -tagged) mutant, with a predicted molecular mass of 35.28 and 36.74 kDa for each monomer, respectively, demonstrated that PfMDH-V190W was able to insert itself into a pre-formed wild-type PfMDH assembly (Lunev et al., 2018) . As shown by subsequent activity assays, the isolated wild-type:V190W chimera possessed no detectable activity in either direction, while recombinant wild-type PfMDH displayed both reductive and oxidative activity. These data demonstrate that recombinant mutants can be used as specific modifiers of wild-type PfMDH activity in vitro, offering the potential to validate it as a drug target, without recourse to complex genetics or initial tool compounds that may display significant off-target effects (Lunev et al., 2018) . However, neither PfAspAT nor PfMDH has as yet been validated as a drug target in vivo.
In this study, structural information of the enzymes PfMDH and PfAspAT was used to generate mutants for use in in vivo protein interference experiments following two different approaches.
In the first approach, we designed mutants that would incorporate within the native oligomer and disrupt the native oligomeric state, thereby inhibiting the function of the native assembly. In a second complementary approach, a mutant was designed to incorporate within the native oligomer and inhibit its function, without disruption to the native oligomeric state. In both approaches, the activity of the target enzymes was determined within the lysate of transgenic parasites, suggesting successful incorporation of the mutants within the targeted assemblies. The resulting data clearly indicate a significant dependence of the parasite on functional aspartate metabolism. Our data also provide proof-of-principle for protein interference assay (PIA) as a general approach to the use of oligomeric assemblies to obtain functional data in vivo.
| RE SULTS
2.1 | The oligomeric interface of PfAspAT shows higher sequence diversity than its active site BLAST (Altschul, Gish, Miller, Myers, & Lipman, 1990) analysis of the close homologs of PfAspAT showed overall 38.7% sequence conservation, while the residues comprising the active site of
PfAspAT showed a sequence conservation of 100% (Table 1 ; Figure 1 ). PISA (Krissinel & Henrick, 2007) analysis of the structural assembly of PfAspAT identified 98 residues involved in the inter-oligomeric contact, showing sequence conservation of 34.7% (Table 1) , where 10.2% accounts for the active site residues.
As previously mentioned (Wrenger et al., 2011) 
| Point mutations of the key active site residues abolish catalytic activity of PfAspAT in vitro while not disturbing the dimerization and overall fold
Based on the crystal structure of PfAspAT (3K7Y; Wrenger et al., 2011) , point mutations were designed in order to interfere with the catalytic TA B L E 1 Sequence conservation across the different oligomeric interfaces of PfAspAT. Sequence conservation amongst close homologs (identity above 28%) was analyzed using BLAST (Altschul et al., 1990) . Analysis of the residues supporting the oligomeric contact was performed using PISA (Krissinel & Henrick, 2007) (Krissinel & Henrick, 2007) . (c) and (e) (side view) Evolutional diversity of the residues involved in the oligomeric contact: absolutely conserved (red), strongly conserved (orange) and slightly conserved (pale yellow). Sequence conservation amongst close homologs (identity over 28%) was analyzed using BLAST (Altschul et al., 1990) . This represents an approx. 170-fold reduced catalytic activity of mutant ( Figure 5 ). These data suggest that the introduction of two-point mutations Y68A and R257A would have the desired inactivation effect on PfAspAT while not affecting its folding or ability to form dimers.
| Inactivated
PfAspAT mutant copies can be incorporated into the native assembly during recombinant expression in E. coli
Assuming that double mutation Y68A/R257A affects both active sites of one PfAspAT dimer, we further hypothesized that formation of PfAspAT wild-type/mutant chimera would also affect both active sites and result in a significantly less active enzyme.
The PfAspAT-Y68A/R257A gene was sub-cloned into the pBM1 vector using sequence-specific primers (Appendix 1) and the Further activity measurements indicated that Strep-purified sample showed reduced activity compared to the wild type; while no activity could be detected from the His 6 -purified sample ( Figure 5c ).
These data indicate that single His 6 -purification of the wild-type:mutant PfAspAT co-expression product is able to isolate a chimeric oligomer consisting of the His 6 -tagged PfAspAT-Y68A/R257A mutant and Strep-tagged wild type. The lack of detectable activity of the purified chimera, confirms the hypothesis that a mutant copy (Y68A/R257A) can be introduced into the native PfAspAT dimeric assembly through co-expression resulting in an inactivated chimeric protein.
| Introduction of PfAspAT and PfMDH mutants results in a significant reduction in parasitaemia in aspartate-limited culture media
The cytosolic localization of PfAspAT within the parasite has previously been reported (Wrenger et al., 2011) . Similarly, the
PfAspAT active site structure, in which the substrate analog maleic acid was modeled based on a homologous structure of chicken AspAT (2CST; Malashkevich et al., 1995) superimposed with PfAspAT. Residues forming the active site cavity are shown in green; residues from the adjacent subunit complementing the active site are shown in cyan and labeled with asterisks. Figures were prepared using PyMol (Delano, 2018) cytosolic localization of PfMDH has been visualized by expression of a PfMDH-GFP chimera ( Figure 6 ). In order to assess the effect of the presence of mutated PfAspAT and PfMDH in vivo, expression plasmids for PfAspAT-Y68A/R257A and PfMDH-V190W were created for transfection into P. falciparum. As the expression from the introduced plasmids is likely to result in an excess of the mutant protein with respect to the endogenous protein, it is not unreasonable to hypothesize that a significant proportion of the wild-type oligomeric (Figure 7a,b) . However, this demonstrates that there are no significant negative effects of introducing either the plasmids or the mutant proteins in vivo in terms of effects on parasite growth. While no effect is observed when both mutant proteins are introduced simultaneously in aspartate-rich media, a significant effect (an almost 100-fold reduction in parasitaemia) is seen on parasite proliferation in aspartate-limiting cultures ( Figure 7c ). As neither mutant alone showed any negative effect on parasite growth in aspartate-limited media, we interpret this data to mean that we have successfully inhibited both PfMDH and PfAspAT in vivo. As indicated above, our approach is unlikely to result in complete inhibition of either
PfAspAT or PfMDH so the residual growth seen in the mutant-inhibited cultures is most probably due to residual activity of uninhibited
PfAspAT and PfMDH. Subsequently, to prove that the double-transfect cell line expresses the transgenic proteins the overexpression of both transcripts was determined by qRT-PCR. Compared to the wildtype strain the mdh-and aspat-genes were 1.64-fold ±0.32 and 4.10-fold ±0.59 higher at the transcriptional level, respectively (Figure 8 ).
Furthermore, the protein production within the transgenic parasites was visualized by western blotting from parasite lysate ( Figure 9 ).
| Activity measurements of PfMDH and PfAspAT in parasite lysates confirm the formation of the heterocomplexes
In order to confirm the activity profile of both enzymes in the respective transfected parasites, we performed specific activity assays using parasite extracts ( Figure 10 ). As expected, proteins extracted from parasites transfected with plasmids encoding additional copies of wild-type PfMDH or PfAspAT genes presented a statistically higher enzymatic activity (100.41 ± 1.05 and 8.83 ± 0.28 mU/mg, respectively) compared to non-transfected parasites (3D7), confirming that both enzymes were not only being overexpressed (Figure 10a) but were also functional. The proteins extracted from parasites transfected with the mutant gene PfMDH-V190W showed a mild reduction in specific activity (68.78 ± 8.65 mU/mg) compared to the control (76.06 ± 0.68 mU/mg, Figure 10a ). However, this difference was not statistically significant. The effect of the transfection with
PfAspAT-Y68A/R257A mutant was more pronounced (3.32 ± 0.06 
| D ISCUSS I ON
In order to show the use of oligomeric surfaces in establishing protein interference studies in an in vivo setting, we have characterized the assembly surfaces of two plasmodial enzymes: aspartate aminotransferase (PfAspAT) and malate dehydrogenase (PfMDH), that are both localized in the cytosol of the parasite (Figure 6a ; Wrenger et al., 2011) . In order to validate the druggability of the targeted malate-aspartate pathway, structure-based mutagenesis experiments of the two involved genes were performed. We have recently demonstrated that a surface mutation in PfMDH, where valine 190 was mutated into tryptophan, disrupted the A-C interface as anticipated, causing significant activity loss (Lunev et al., 2018) . Our previous data suggested that the introduction of the V190W mutation at the oligomeric interface (A-C) not only caused the splitting F I G U R E 5 (a) SDS-PAGE for Strep-tagged wild-type PfAspAT (Lane 1) and His 6 tagged PfAspAT Y68A/R257A mutant (Lane 2) both purified from a co-expression in E. coli. (b) western blot analysis shows that the wild-type PfAspAT (Strep-tagged) and its inactive double mutant (Y68A/R257A, His 6 -tagged) form a stable complex during co-expression in E. coli. Lanes 1 and 3 contain samples purified using Niaffinity chromatography, while Lanes 2 and 4 contain samples purified using Strep tactin-affinity chromatography. Lanes 1 and 2 and 3 and 4 were probed using a His 6 antibody or Strep-antibody respectively. The activities of the two eluates were then compared to that of the wildtype. (c) Specific activity of the wild-type PfAspAT was similar to the previously reported value (Wrenger et al., 2011) ; Strep-purified sample (selection for chimeras and wild-type protein only) from co-expression of Strep-tagged WT and His 6 -tagged PfAspAT-Y68A/R257A showed decreased activity, whereas no activity could be detected in the Ni-NTA purified sample (selection for chimeras and inactive mutant only). GraphPad Prism 5.0 was used for one-way ANOVA analysis F I G U R E 6 (a) Cytosolic localization of PfMDH visualized inside the parasite by expression of a PfMDH-GFP chimera.
(b) Protein expression of the transgenic cell line PfMDH-GFP chimera verified via western blot, the chimera has a molecular weight of 61.5 kDa of the tetramer into a pair of dimers but it also made the re-formation of the tetramer highly unlikely due to the introduction of molecular clashes. It was also previously reported that the mutated PfMDH-V190W was able to incorporate into the native PfMDH-WT assembly in vitro, disturbing the native oligomeric state of the target protein as well as inhibiting its activity (Lunev et al., 2018) . In this work, we also demonstrate that the hypothesized PfMDH chimeras are formed inside the parasite in vivo, through measurement of PfMDH activity in the lysate of transgenic parasites.
We performed similar experiments with PfAspAT. In contrast with
PfMDH where the oligomeric state is disturbed, in our PfAspAT mutant, the native oligomeric state is maintained. Incorporation of mutant
PfAspAT showed that the enzyme's native oligomeric assembly could also be utilized in order to target the wild-type protein and show an effect on activity in vitro ( Figure 5c ) and in vivo (Figure 10 ). The inactive
PfAspAT-Y68A/R257A mutant was shown to be able to incorporate into native PfAspAT-WT dimeric assembly during recombinant co-expression, as confirmed by western blot (Figure 5b ), resulting in complete loss of activity (Figure 5c ). The mutated PfAspAT protein was then expressed in P. falciparum blood-stage cultures, and we have demonstrated that the hypothesized PfAspAT chimeras are formed inside the parasite in vivo, through measurement of PfAspAT activity in the lysate of transgenic parasites. While no effect is seen in aspartate-rich media, the introduction of both mutant proteins in aspartate-limited media results in a clear phenotype (Figure 7) , without recourse to complex genetic manipulations. We have termed this approach the oligomeric protein interference assay (PIA; Meissner et al., 2016) .
Our data show that oligomeric surfaces can be used to specifically inhibit protein activity in vivo, especially in cases when opportunities for genetic manipulation are limited. The introduction of
PfAspAT-Y68A/R257A or PfMDH-V190W alone did not result in any significant effect on parasite proliferation in blood-stage cultures (Figure 7a,b) . Nonetheless, we believe that these findings demonstrate that the expression of mutant proteins in cultured parasites has overall no negative effects on parasite growth. This also indicates that, while the expression levels of the mutant proteins are significantly higher (up to fourfold) than their endogenous counterparts, they are likely not overexpressed at a level that would induce metabolic stress on P. falciparum through depletion of amino acids.
As the mutant proteins introduced are designed and demonstrated to be inactive, it is also highly unlikely that we have significantly Similarly, no significant effect of PfMDH-V190W introduction was observed. (c) While no effect of double transfection with PfMDH-V190W and PfAspAT-Y68A/R257A was observed in aspartate-rich media, the parasite's viability was significantly hampered in the aspartate-limited culture (p < o.oo1). Two-way ANOVA analysis was performed using <>GraphPad Prism 5.0 Müller et al., 2009 ). The lack of negative effect on the proliferation of culture parasites is supported by the measurements of specific activity of both enzymes in lysates of parasites transfected with the mutant genes, which show that these parasites retain a partial activity of both enzymes (Figure 10a,b) . Additionally, continuous expression of the inserted mutant reduces the risk of possible degradation of the mutant protein by cellular proteases before it reaches the intended targets. Further, our mutations were designed to result in inactive proteins (confirmed by our in vitro activity assays (Lunev et al., 2018) , Figure 3c ). In fact, the activity assay in lysates of parasites supports not only the hypothesis that the introduction of mutated proteins will cause a decrease in the activity, but also indicates that the formation of heterocomplexes occurs in vivo, thereby influencing the function of the native protein.
Finally, in contrast to current small molecule inhibition approaches, no limitations regarding drug or compound delivery to the cytosol are encountered as the mutant proteins are expressed directly within the parasite. Based on this analysis, we believe that the introduction of inactive proteins specific for oligomeric targets represents a minimally perturbing method to specifically inhibit metabolic pathways of interest in the human malaria parasite P. falciparum that will have a minimal off-target effect, and, in this manner, offers a possible tool to be used in the validation of target candidates.
While the insertion of the individual mutations of PfMDH or
PfAspAT results in no negative effect on parasitemia, the transfection of parasites with both plasmids results in a significant reduction in parasite proliferation in aspartate-limited media (Figure 7c ). This is a clear change in phenotypic behavior that has been generated without recourse to complex genetic approaches. These data strongly the human serum, with recent measurements suggesting that the concentration of L-aspartate in human sera is <20 µM (Psychogios et al., 2011) . This strongly suggests that biosynthetic pathways would be the main source of the aspartate required by P. falciparum in the human host (Figure 11 ).
The significant drop in proliferation upon oligomeric-based inhibition of both PfMDH and PfAspAT in aspartate-limited cell culture media suggest that aspartate biosynthesis in the malarial parasite depends upon the function of both of these enzymes and validates this metabolic pathway as drug target in P. falciparum. This is in accord with recent data that suggest the products of glycolysis (both pre-and post-mitochondrial) are used in biosynthesis in the malarial parasite (Ke et al., 2015) . In another recent study (Zhang et al., 2018) , mutagenic index scores (MISs) calculations have predicted PfMDH as an essential enzyme. In contrast, the PIA experiments revealed no effect on the proliferation of MDH mutant overexpressing parasites. However, this down-regulation of intra-cellular MDH activity will not warrant a total "knock-down" of the plasmodial MDH due to the presence of residual endogenous wild-type MDH. On the other hand, the MIS approach suggested PfAspAT as non-essential, corroborating with our data, which shows no effect on the knock-down of
PfAspAT alone although an intra-cellular simultaneous over-expression of PfAspAT and PfMDH mutated proteins clearly causing a severe growth defect. While the simultaneous inhibition of two enzymes may be highly challenging for the development of novel antimalarials, our data strongly suggest that future drug targets to treat malaria infection may be found within downstream components of the aspartate metabolism pathway (Figure 11 ). Taken together, our data also show that oligomeric surfaces offer a highly promising opportunity to specifically influence protein behavior in vivo and offer a novel avenue in the validation of pathways for downstream drug development, particularly in the field of infectious diseases.
| MATERIAL AND ME THODS

| Expression and purification of recombinant PfAspAT
The purification of PfAspAT has been previously reported (Jain et al., 2010) . Wild-type PfAspAT open reading frame (ORF) was cloned into pASK-IBA3 expression plasmid with additional C-terminal His 6 -tag to facilitate purification via Ni-NTA chromatography. The generated pASK-IBA3-PfAspAT plasmid was transformed into the commercially F I G U R E 1 0 Specific activity values of PfMDH (a) and (b) PfAspAT, respectively, measured from Plasmodium falciparum cell lysates. The activity of the wild-type MDH (a) was significantly higher compared to the V190W mutant (p < 0.05). The activity of AspAT-WT (b) was significantly higher compared to both control (3D7) and double mutant (p < 0.05). Mutant PfAspAT transfectant showed lower activity compared to the control (3D7; p < 0.05). The activity was measured in triplicates, in two independent experiments. GraphPad Prism 5.0 was used for one-way ANOVA analysis F I G U R E 11 Importance of the aspartate metabolism in Plasmodium falciparum. Our experiments showed that inhibition of the de-novo aspartate biosynthesis via PfMDH and PfAspAT is a viable target for future antimalarial drug design available E. coli expression strain BLR (DE3; Novagen) for expression.
After expression, the cells were lysed using sonication and centrifuged to separate the lysate. Soluble His-tagged PfAspAT was purified using Ni-NTA agarose (Quiagen) according to the manufacturer's recommendations. PfAspAT was further purified via size-exclusion chromatography using HiLoad 16/60 Superdex S75 column (GE Healthcare).
| Site-directed mutagenesis
The single mutants PfAspAT-Y68A and PfAspAT-R257A, and the double mutant PfAspAT-Y68A/R257A were generated via site-directed mutagenesis using specific oligonucleotides containing the altered codons (Appendix 1) and the pASK-IBA3-PfAspAT plasmid (Jain et al., 2010) as a template. All constructs were verified by Sanger sequencing.
| Determination of oligomeric state
The analysis of the oligomeric state of recombinant WT PfAspAT and mutants was performed according to the previously described protocol (Wrenger et al., 2011) . 
| In vitro activity assays
The specific activity of the double mutant of PfAspAT-Y68A/R257A
was measured following the same procedure as previously reported (Wrenger et al., 2011) . The effect of incorporation of mutant His 6 -tagged PfAspAT-Y68A/R257A into the native Strep-tagged wild-type assembly was also analyzed using the samples of the coexpression experiments (described above).
| Cloning and transfection of PfMDH
V190W and PfAspAT Y68A, R257A
In order to obtain transgenic parasites, the ORFs of WT-PfAspAT and PfAspAT-Y68A/R257A were amplified via PCR using sequence-specific primers (Appendix 1) and subsequently cloned into pARL 1a-with the hDHFR (human dihydrofolate reductase) resistance cassette (Wrenger & Müller, 2004) . The resulting plasmids encoded for the full-length WT-PfAspAT and PfAspAT-Y68A/ R257A mutant with an additional C-terminal Strep-tag followed by the stop-codon before the GFP gene encoded on pARL 1a-.
Similarly, WT-PfMDH and the PfMDH-V190W mutant with C-terminal His 6 -tag (cloning procedure described in (Lunev et al., 2018)) were cloned into pARL 1a-with BSD (Blasticidin S) resistance cassette in order to facilitate double transfection (Knöckel et al., 2012) .
In order to determine WR992010 and Blasticidin S drug-selection effects, two MOCK plasmids were generated (pARL-MOCKhDHFR, pARL-MOCK-BSD) as described in (Knöckel et al., 2012) . All constructs were confirmed by automatic sequencing (Sanger) before transfection into P. falciparum. The transfection of the resulting constructs pARL-PfAspAT-Y68A/R257A-Strep-hDHFR, pARL-PfMDH-V190W-his-BSD, pARL-MOCK-hDHFR and pARL-MOCK-BSD was performed into ring stage P. falciparum 3D7 as described in (Knöckel et al., 2012; Müller et al., 2010) . The co-transfected cell lines were generated using the stabilized parasites previously transfected with pARL-PfAspAT-Y68A/R257A-Strep-hDHFR or pARL-MOCK-hDHFR, which were then electroporated with pARL-PfMDH-V190W-his-BSD or pARL-MOCK-BSD plasmids, respectively. The selection of transgenic parasites was performed using 5 nM of WR99210 and 1 μg/ml Blasticidin S. Transfected parasites were maintained in continuous culture using the conditions of Trager and Jensen modified as described in (Das et al., 2005) .
| qRT and western blot
An asynchronous culture of transgenic 3D7 parasites was isolated via saponin lysis. The total RNA of these parasites was extracted using TRIZOL following the manufacturer's instruction. The cDNA synthesis was performed as described in (Butzloff, 2013; Chan et al., 2013; Knöckel et al., 2012; Müller et al., 2010) . The quantitative real-time PCR was performed using specific primers (Appendix 1), that identify products from 150-190 bp. Briefly, 2 μl of each primer (5 pmol/μl) were used together with 9 μl of 2.5× Real Master Mix SYBR (20×; 5Prime), 6 μl RNAse-free dH 2 O and 1 μl cDNA (50 ng/ μl). The reaction was performed in a thermocycler (Corbett Cycler) with the following program: 2 min 95°C followed by 35 cycles of 95°C for 15 s, 49°C for 20 s and 69°C for 20 s, and a final step of 95°C for 2 min. Normalization and calibration were performed using the aldolase gene (Salanti et al., 2003) and the respective MOCK cell line like (Chan et al., 2013) . The data were analyzed using the Corbett Rotor-Gene 6.1.81 software and the 2 −ΔΔCt method (Livak & Schmittgen, 2001 ).
The protein expression of the transgenic cell lines was verified via western blot analysis as described in (Knöckel et al., 2012) . Briefly, isolated parasites were resuspended in 5x SDS-PAGE sample buffer, boiled for 5 min at 95°C and centrifuged for 5 min at 14,000 ×g. The supernatant was separated by 10% SDS-PAGE and transferred on a nitrocellulose membrane (Bio-Rad). The expressed proteins were detected via their Strep-or His 6 -tag by using a monoclonal anti Strepor anti-His antibody (1:5,000 dilution (IBA; Pierce) and a secondary anti-mouse HRP-labeled antibody (1:10,000 dilution; Pierce) and visualized on X-ray films using the SuperSignal West Pico detection system (Thermo Scientific).
| Activity assays from parasites lysate
In order to analyze the specific activity of PfAspAT and PfMDH, Bradford assay (Bradford, 1976) .
| Proliferation assays
In order to analyze the long-term influence of the overexpressing cell lines pARL-PfAspAT-Y68A/R257A-Strep-hDHFR, pARL-PfMDH-V190W-his-BSD and the double transgenic cell line pARL-PfAspAT-Y68A/R257A-strep-hDHFR + pARL-PfMDH-V190W-his-BSD in comparison with their respective MOCK line, parasites growth was monitored over several days. The parasites were synchronized using sorbitol and a starting parasitaemia of 1% of ring-stage iRBC (infected red blood cells) was adjusted. Giemsa-stained thin smears were analyzed daily and the parasitaemia was determined by light microscopy in percentage of iRBC to total RBC. Cultures with more than 8% of iRBC were diluted and cumulative parasitaemias were calculated as described in (Knöckel et al., 2012) . Triple repetition of the proliferation assay was performed and the growth curves were generated with GraphPad Prism 4.0. The slope of the respective curves was calculated through an exponential equation (Müller et al., 2009 ).
| Localization of PfMDH
The ORF of PfMDH-WT with no stop-codon at C-terminus was amplified by PCR and subsequently cloned into pARL 1a-using KpnI/AvrII restriction enzymes (Appendix 1). The resulting plasmid encoded for the wild-type PfMDH fused in front of the GFP gene and was transfected into P. falciparum 3D7 parasites as described above. The localization of the MDH-GFP chimera was analyzed via live cell fluorescent microscopy using an Axio Imager M2 microscope (Zeiss) equipped with an AxioCam HRC digital camera (Zeiss). In order to visualize the nucleus, the parasites were incubated with 10 µg/ml HOECHST 33342 dye (Invitrogen).
The images were analyzed with the AxioVision 4.8 software.
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